10 Essential GLP-1 Brand Names for Weight Management Success

Introduction

Many feel stuck, unsure of which path to take in their weight loss journey. With so many options available, each one claiming to offer hope, yet often leading to confusion and frustration, it’s easy to feel overwhelmed. But with the emergence of GLP-1 medications, there’s a new light on the horizon, offering tailored solutions that cater to individual health profiles. But with so many options, it’s natural to wonder which GLP-1 brand can truly support your unique journey.

In this article, we’ll explore ten essential GLP-1 medications, highlighting their benefits and how they can guide you toward successful weight management.

Innovative Medicine: Personalized GLP-1 Solutions for Weight Management

Many people struggle to find effective solutions for managing their body composition, often feeling overwhelmed by the options available. At Innovative Medicine, we recognize that each person's journey is unique. Our treatment plans featuring GLP-1 brand names are tailored to meet your unique needs, blending the latest medical advancements with a caring approach that puts you first. By focusing on your individual health profile, we ensure that each treatment plan is customized to promote effective fat reduction while addressing any underlying health concerns.

We offer a range of supportive programs, like low-carb diets and the Innovative Protein program, to help you achieve your goals in a way that feels right for you. Our dedicated team works closely with you to monitor your progress and adjust treatments as necessary, ensuring a holistic approach that encompasses your physical, mental, and emotional well-being. By choosing our personalized approach, you’re not just addressing body composition; you’re investing in your overall health and happiness. For more information or to schedule a consultation, please contact us at (765) 471-1100.

Ozempic: A Leading GLP-1 for Weight Loss and Diabetes Control

Many individuals feel overwhelmed by the challenges of obesity and diabetes, struggling to find effective solutions that truly work for them. Ozempic is one of the GLP-1 brand names that is a once-weekly injection many people are turning to for help with weight loss and managing Type 2 diabetes. Ozempic, which is among the GLP-1 brand names, helps control appetite and glucose levels by mimicking the GLP-1 hormone, leading to a significant reduction in body weight. In fact, studies show that those who use Ozempic can lose about 15% of their body weight in just a year, giving them hope and a fresh start. This dual action not only aids in managing body composition but also improves glycemic control, making it a valuable option for individuals facing obesity and diabetes.

Testimonials from patients at Innovative Medicine highlight the medication's effectiveness and the compassionate care they receive. One patient shared, "Dr. Charles Turner changed my life! He listened to how I was feeling and adjusted my meds until I felt good." Another remarked on the attentive staff, stating, "Everyone that works there is super friendly. Dr. Turner and his team of other Doctors are great and spend time listening." These experiences demonstrate how Innovative Medicine's personalized and comprehensive approach transforms health journeys, establishing it as a reliable option for those pursuing effective solutions for managing their body. By choosing Innovative Medicine, you're not just getting a treatment; you're joining a caring community that supports you every step of the way to better health. For inquiries or to schedule an appointment, please call (765) 471-1100.

Wegovy: Targeted GLP-1 Treatment for Effective Weight Management

For many, the journey to weight loss feels overwhelming and discouraging, especially after countless attempts that lead to little success. Wegovy (semaglutide) is a powerful GLP-1 receptor agonist and one of the notable GLP-1 brand names specifically created for chronic management of body composition, aligning perfectly with Innovative Medicine's commitment to personalized healthcare solutions. This higher-dose formulation helps you feel fuller and reduces hunger, making it easier to lose weight.

In recent clinical trials, participants using Wegovy experienced an average reduction of 15% to 20% in body mass over a 68-week period. If you’ve struggled to lose weight with traditional diets and exercise, this medication could be the answer you’ve been looking for. Significantly, the OASIS 4 trial revealed that 93.2% of participants on semaglutide 7.2 mg, one of the GLP-1 brand names, achieved at least a 5% reduction in body mass, highlighting its efficacy as a transformative treatment choice for those facing challenges with body composition.

At Innovative Medicine, we’re here to support you every step of the way, integrating Wegovy into personalized programs designed to help you achieve a healthier lifestyle. Furthermore, Wegovy has been associated with improvements in glycemic control and reductions in cardiovascular risk factors, making it a comprehensive solution for individuals facing obesity challenges.

The FDA's recent endorsement of Wegovy's new higher-dose injection on March 19, 2026, further strengthens its position as one of the prominent GLP-1 brand names in obesity treatment, providing patients with a powerful tool in their management journey. With Wegovy, you’re not just choosing a treatment; you’re embracing a supportive partner in your journey toward a healthier life.

Mounjaro: Innovative GLP-1 for Weight Management and Diabetes

For those struggling with weight management and blood sugar control, finding an effective solution can feel overwhelming. Mounjaro (tirzepatide) is one of the GLP-1 brand names that offers a promising path, acting as a GLP-1 treatment that supports fat reduction while enhancing blood sugar regulation. By activating both GLP-1 and GIP receptors, it boosts insulin secretion and curbs appetite, helping many regain control over their health.

Clinical studies, including the SURMOUNT-3 trial, reveal that participants can achieve a total mean loss of 26.6% over 84 weeks, with an average reduction of 20% over 72 weeks. Many individuals experience reductions in mass of 15-22% depending on dosage, reflecting the effectiveness of this treatment.

While the promise of weight loss is enticing, the fear of side effects can leave many feeling uncertain. It's important to be aware that Mounjaro may cause gastrointestinal side effects and has warnings regarding potential thyroid tumors and pancreatitis. Yet, with the right guidance and support, many find that the benefits far outweigh the risks.

As Dr. Jeff Emmick noted, individuals who incorporated tirzepatide into their diet and exercise experienced greater, longer-lasting reductions in body mass than those receiving a placebo. With Mounjaro, many are discovering a path to better health, one that balances effectiveness with careful consideration of their well-being.

Trulicity: Effective GLP-1 for Weight Loss and Glycemic Control

Living with Type 2 diabetes and obesity can feel overwhelming, leaving many searching for effective solutions. Trulicity (dulaglutide) is one of the GLP-1 brand names that serves as a once-weekly injectable treatment primarily for controlling Type 2 diabetes, while also showing considerable promise for reducing body mass.

Clinical studies reveal that patients using Trulicity can experience an average reduction of approximately:

1. 6.8 pounds with the 1.5 mg dose
2. 8.8 pounds with the 3.0 mg dose
3. 10.4 pounds with the 4.5 mg dose over several months.

While it is not specifically authorized for body composition control, many individuals report weight reduction as a beneficial secondary effect. Not only does Trulicity help manage your blood sugar levels, but it also supports your journey toward a healthier weight, giving you hope and control over your health.

The AWARD-11 clinical trial emphasized that higher doses of Trulicity, among other GLP-1 brand names, led to significant A1C reductions and consistent reductions in body mass, further reinforcing its role in diabetes care and body composition control.

It is important for patients to monitor for potential side effects, such as hypoglycemia and acute pancreatitis, to ensure safe and effective treatment. With careful monitoring and the right support, Trulicity can be a key ally in your journey toward better health and well-being.

Saxenda: GLP-1 Designed Exclusively for Weight Management

For those struggling with weight management, GLP-1 brand names like Saxenda (liraglutide) offer a promising solution that can help reshape your journey. This daily injectable treatment mimics the GLP-1 hormone, which is featured in several GLP-1 brand names and plays a crucial role in regulating appetite and food intake. In fact, many participants in the SCALE studies - over 5,000 of them - have found that Saxenda helped them reduce their body mass by an average of 5% to 10% in just a year.

While Saxenda offers promising results, some patients may worry about potential side effects. It's important to acknowledge that serious side effects have been reported during trials, including pancreatitis and gallbladder disease. Yet, with proper guidance and monitoring, many find Saxenda to be a safe and effective part of their weight management journey. This treatment is especially beneficial for individuals who have not reached their goals through diet and exercise alone, providing a targeted strategy for body composition.

Saxenda is one of the GLP-1 brand names that play a vital role in the fight against obesity, which affects over a third of adults in the U.S. and leads to serious health complications such as heart disease and type 2 diabetes. With Saxenda, you’re not just choosing a treatment; you’re embracing a supportive partner in your journey toward a healthier life. According to the FDA, Saxenda is designed for long-term control of body composition, alongside a reduced-calorie diet and increased physical activity.

Victoza: Dual-Action GLP-1 for Diabetes and Weight Loss

Managing diabetes and obesity can feel like an uphill battle, leaving many searching for effective solutions that truly work. Victoza (liraglutide) is a medication, among the various GLP-1 brand names, that many have found helpful in managing Type 2 diabetes, and it’s also shown promise in helping with weight loss for numerous patients. While Victoza isn’t officially approved for weight loss, studies show that many patients can lose between 5% and 8% of their body mass while using it. This means that Victoza, one of the GLP-1 brand names, not only helps manage blood sugar levels but also supports weight loss, making it a valuable option for those dealing with both diabetes and obesity.

At Innovative Medicine, we take an innovative and personalized approach to treatment, ensuring that each patient receives comprehensive care tailored to their unique needs. Our services include:

• Weight Loss
• Testosterone therapy
• Female Hormones
• Pain management
• And more

As Dr. Charles Turner, MD, leads our compassionate team, one patient shared, "Dr. Turner took the time to understand my feelings and adjusted my medications until I felt better," highlighting our commitment to attentive and effective healthcare. Our team is dedicated to delivering effective solutions for body composition and hormonal imbalances, establishing us as a reliable partner in your health journey. Choosing Victoza, among the GLP-1 brand names, could be the turning point in your health journey, offering a path toward better management of both diabetes and body composition.

Rybelsus: The First Oral GLP-1 for Weight Management

Managing Type 2 diabetes and body weight can feel like an overwhelming challenge for many, leaving individuals searching for effective solutions. Rybelsus (semaglutide) offers a groundbreaking oral option for those managing Type 2 diabetes, showing promise in helping with weight management as well. While it’s not specifically indicated for weight loss, studies reveal that patients taking Rybelsus can shed an average of 5 to 8 pounds over six months. Its oral formulation provides a convenient alternative for those who prefer not to use injections, making it an attractive option for individuals aiming to manage their body composition and blood sugar levels.

At Innovative Medicine, we’re dedicated to creating personalized treatment plans that truly cater to your unique needs. Patient testimonials highlight the compassionate care provided by our skilled team, reinforcing the effectiveness of Rybelsus as part of a holistic strategy for managing body composition. In comparison, other treatments, which are GLP-1 brand names like Zepbound and Wegovy, have shown higher average loss percentages in clinical studies, with Zepbound achieving over a 20% reduction.

With the rise of new oral GLP-1 treatments, Rybelsus stands out among the GLP-1 brand names as a dependable choice for those looking to improve their health and well-being. According to specialists, the simplicity of use and the potential for substantial health enhancements strengthen Rybelsus's role in the changing environment of obesity therapies. As the landscape of obesity therapies evolves, Rybelsus stands out as a reliable choice for those ready to take charge of their health journey.

Byetta: A Historical GLP-1 Medication in Weight Management

Many individuals struggle with the challenges of managing Type 2 diabetes and the associated weight issues, feeling overwhelmed by their options. For many, managing Type 2 diabetes feels like an uphill battle, but Byetta (exenatide) offers a promising path forward. While it’s not specifically approved for weight management, many patients have found that Byetta can help them shed an average of:

1. 6 pounds on the 5 mcg dose
2. 7 pounds on the 10 mcg dose

over six months, bringing them closer to their health goals. Since its FDA approval in 2005, Byetta has marked a significant milestone in the journey toward better management of diabetes, offering hope to many. This progress in GLP-1 therapies underscores the importance of GLP-1 brand names, such as Byetta, for those seeking to improve their health and well-being.

Zepbound: The Latest GLP-1 Innovation for Weight Management

Many individuals battling obesity feel overwhelmed and frustrated by their weight loss journey, searching for effective solutions that truly work. Zepbound (tirzepatide) stands out as the latest advancement in GLP-1 brand names, specifically designed for effective management of body composition. Clinical trials have shown that Zepbound can enable an impressive average reduction of 20.2% over a 72-week period, placing it among the most effective options available for obesity treatment. This innovative treatment helps control appetite and improve glucose levels, providing a well-rounded approach to tackling obesity.

In the SURMOUNT-5 trial, participants using Zepbound achieved an average reduction of 50.3 pounds, significantly surpassing the 33.1 pounds lost by those on semaglutide (Wegovy). With 32% of Zepbound users experiencing a reduction of 25% or more, this treatment signifies a significant advancement in GLP-1 therapy, showcasing the effectiveness of various GLP-1 brand names in the ongoing fight against obesity.

We believe that while Zepbound can help you shed pounds, it’s important to combine it with personalized plans and lifestyle changes for lasting success. Imagine taking the first step toward a healthier you with Zepbound, a treatment that could change your life for the better. For more information on how Zepbound can fit into your weight management journey, contact us at (765) 471-1100.

Conclusion

If you’ve ever felt frustrated by weight management, you’re not alone. Many individuals seeking effective weight management solutions can find hope in the innovative GLP-1 brand names discussed in this article. Medications like Ozempic, Wegovy, and Mounjaro provide personalized approaches to weight loss and diabetes management. They focus on what works best for you. By integrating these treatments into comprehensive health plans, patients can experience significant improvements in their body composition and overall well-being.

Throughout the article, key insights highlight the effectiveness of various GLP-1 medications. Ozempic and Wegovy have shown remarkable results in clinical trials, with participants achieving substantial weight loss and improved glycemic control. Mounjaro and Trulicity also provide dual benefits for those managing diabetes and obesity, while Saxenda and Rybelsus offer additional options for individuals seeking to enhance their weight management journey. The testimonials from patients at Innovative Medicine further reinforce the value of compassionate care and personalized treatment plans.

Your journey to effective weight management is about more than just losing weight; it’s about embracing a healthier lifestyle and investing in your long-term well-being. With the support of Innovative Medicine's dedicated team, individuals can explore these GLP-1 options and find the right fit for their unique needs. If you’re ready to take that next step, call Innovative Medicine at (765) 471-1100. Your transformative health journey starts with a simple conversation.

Frequently Asked Questions

What is Innovative Medicine's approach to weight management?

Innovative Medicine offers personalized treatment plans featuring GLP-1 solutions tailored to individual health profiles, focusing on effective fat reduction and addressing underlying health concerns.

What supportive programs does Innovative Medicine provide?

Innovative Medicine provides supportive programs such as low-carb diets and the Innovative Protein program to help individuals achieve their weight management goals.

How does Innovative Medicine ensure a holistic approach to treatment?

The dedicated team at Innovative Medicine works closely with patients to monitor progress and adjust treatments as necessary, encompassing physical, mental, and emotional well-being.

What is Ozempic and how does it help with weight loss?

Ozempic is a GLP-1 medication that is administered as a once-weekly injection, helping to control appetite and glucose levels, leading to significant weight loss and improved glycemic control.

What results can patients expect from using Ozempic?

Studies show that individuals using Ozempic can lose about 15% of their body weight in just a year.

What do patients say about their experiences at Innovative Medicine?

Patients have shared positive testimonials about the compassionate care and attentive staff, highlighting the personalized approach and effective treatment they receive.

What is Wegovy and how does it assist in weight management?

Wegovy (semaglutide) is a GLP-1 receptor agonist designed for chronic management of body composition, helping individuals feel fuller and reducing hunger, which facilitates weight loss.

What are the clinical trial results for Wegovy?

In clinical trials, participants using Wegovy experienced an average reduction of 15% to 20% in body mass over 68 weeks, with 93.2% achieving at least a 5% reduction.

What additional benefits does Wegovy provide?

Wegovy has been associated with improvements in glycemic control and reductions in cardiovascular risk factors, making it a comprehensive solution for obesity challenges.

When was Wegovy's new higher-dose injection endorsed by the FDA?

The FDA endorsed Wegovy's new higher-dose injection on March 19, 2026, enhancing its role in obesity treatment.

List of Sources

1. Innovative Medicine: Personalized GLP-1 Solutions for Weight Management
   • Amazon One Medical introduces weight management program with upfront GLP-1 medication costs (https://aboutamazon.com/news/retail/amazon-glp1-management-program)
   • GLP-1 Weight Loss Medications Could Become More Affordable (https://grandhealthpartners.com/glp-1-weight-loss-announcement)
   • Innovative New Medicines Are Finally Providing Treatments for Obesity (https://uschamber.com/health-care/innovative-new-medicines-are-finally-providing-treatments-for-obesity)
   • 5 Projected GLP-1 Trends in 2026 - GoodRx (https://goodrx.com/classes/glp-1-agonists/glp-1-trends?srsltid=AfmBOooM_PQRCo2MxOPJzOb_whsJ4newQV5WmqY4Lz0bJnXmaR-ctweY)
   • How Supply and Demand for Weight Loss Drugs is Playing Out in 2026 (https://jpmorgan.com/insights/global-research/current-events/obesity-drugs)
2. Ozempic: A Leading GLP-1 for Weight Loss and Diabetes Control
   • People who stop taking GLP-1 drugs regain weight faster, review finds | CBC News (https://cbc.ca/news/health/weight-regain-weight-medications-glp1-9.7037276)
   • Key GLP-1 Statistics & Trends In 2026 (https://forbes.com/health/weight-loss/glp-1-statistics)
   • Blockbuster weight loss drugs like Ozempic deliver big results but face big questions (https://sciencedaily.com/releases/2026/02/260211073033.htm)
   • Clinical trial results show weight loss drug reduces the risk of heart and liver diseases in people with obesity | VCU Health (https://vcuhealth.org/news/clinical-trial-results-show-weight-loss-drug-reduces-the-risk-of-heart-and-liver-diseases-in-people-with-obesity)
   • Ask the expert: The truth about the Ozempic craze (https://msutoday.msu.edu/news/2026/01/ask-the-expert-the-truth-about-the-ozempic-craze)
3. Wegovy: Targeted GLP-1 Treatment for Effective Weight Management
   • FDA Approves Novo Nordisk's Wegovy Pill, the First and Only Oral GLP-1 for Weight Loss in Adults (https://drugs.com/newdrugs/fda-approves-novo-nordisk-s-wegovy-pill-first-only-oral-glp-1-weight-loss-adults-6701.html)
   • Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026 (https://prnewswire.com/news-releases/wegovy-pill-demonstrated-greater-weight-loss-than-orforglipron-and-lower-odds-of-stopping-medication-due-to-side-effects-in-a-new-indirect-comparison-to-be-presented-at-obesity-medicine-association-2026-302732768.html)
   • FDA Approves Oral Wegovy Following Positive Phase III OASIS 4 Trial Results | Applied Clinical Trials Online (https://appliedclinicaltrialsonline.com/view/fda-approves-oral-wegovy-positive-oasis-trial-results)
   • STEP UP Trial Shows Higher Dose of Wegovy Produces Significant Weight Loss in Adults With Obesity Without Diabetes | Applied Clinical Trials Online (https://appliedclinicaltrialsonline.com/view/wegovy-weight-loss-obesity-diabetes)
4. Mounjaro: Innovative GLP-1 for Weight Management and Diabetes
   • FDA approves new version of diabetes drug Mounjaro for weight loss (https://yourcentralvalley.com/news/u-s-world/ap-fda-approves-new-version-of-diabetes-drug-mounjaro-for-weight-loss)
   • Lilly drug Mounjaro succeeds in second weight loss study (https://biopharmadive.com/news/lilly-mounjaro-weight-loss-trial-results-glp-1-ozempic/648670)
   • Lilly's tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks | Eli Lilly and Company (https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-shows-additional-211-weight-loss-after-12)
   • How quickly can you expect results with Mounjaro? (https://numan.com/weight-loss/medication/how-quickly-results-mounjaro)
5. Trulicity: Effective GLP-1 for Weight Loss and Glycemic Control
   • FDA approves additional doses of Trulicity® (dulaglutide) for the treatment of type 2 diabetes (https://prnewswire.com/news-releases/fda-approves-additional-doses-of-trulicity-dulaglutide-for-the-treatment-of-type-2-diabetes-301124206.html)
   • FDA Approves Higher Doses of Trulicity To Help People with Type 2 Diabetes (https://diatribe.org/diabetes-medications/fda-approves-higher-doses-trulicity-help-people-type-2-diabetes)
   • Trulicity & Weight Loss | HCP | Trulicity (dulaglutide) (https://trulicity.lilly.com/hcp/efficacy-weight/weight-loss-dosing)
   • 14 New Weight Loss Drugs - GoodRx (https://goodrx.com/conditions/weight-loss/new-weight-loss-drugs?srsltid=AfmBOoqh8fZGT5V3nxK4UyLoMOnE1x8L4z3_aeLAI5jiqwMkSMifD8OU)
   • New Data Show Lilly's Once-Weekly Trulicity® (dulaglutide) in Combination with Insulin Glargine Improves Glycemic Control in People with Type 2 Diabetes (https://prnewswire.com/news-releases/new-data-show-lillys-once-weekly-trulicity-dulaglutide-in-combination-with-insulin-glargine-improves-glycemic-control-in-people-with-type-2-diabetes-300283293.html)
6. Saxenda: GLP-1 Designed Exclusively for Weight Management
   • Weight-loss drug Saxenda effective for kids as young as 6, study shows (https://apnews.com/article/liraglutide-saxenda-obesity-weight-loss-children-bbd6e47f6c7f725cf0fe92756dc4f092)
   • Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss (https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2025/Teva-Announces-FDA-Approval-and-Launch-of-Generic-Saxenda-liraglutide-injection--First-Generic-GLP-1-Indicated-for-Weight-Loss/default.aspx)
   • Saxenda (liraglutide) for the Treatment of Obesity, US (https://clinicaltrialsarena.com/marketdata/saxenda-liraglutide-obesity)
7. Victoza: Dual-Action GLP-1 for Diabetes and Weight Loss
   • Can Victoza Be Used for Weight Loss? - GoodRx (https://goodrx.com/victoza/victoza-for-weight-loss?srsltid=AfmBOorFxZcz6X6f7njC6Ql3EPndwTfZxFv3hcPxXZod5C1dpwm88t-k)
   • Phase 3a Data Showed Liraglutide 3 mg Demonstrated Significantly Greater Weight Loss Compared to Placebo in Adults With Obesity and Type 2 Diabetes (https://prnewswire.com/news-releases/phase-3a-data-showed-liraglutide-3-mg-demonstrated-significantly-greater-weight-loss-compared-to-placebo-in-adults-with-obesity-and-type-2-diabetes-263151521.html)
   • Novo Nordisk Makes Victoza(R) Commercially Available in the United States (https://prnewswire.com/news-releases/novo-nordisk-makes-victozar-commercially-available-in-the-united-states-84463542.html)
   • Diabetes Drug Shows Promise for Weight Loss (https://uspharmacist.com/article/diabetes-drug-shows-promise-for-weight-loss)
   • News Details (https://novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3213)
8. Rybelsus: The First Oral GLP-1 for Weight Management
   • Press releases (https://novonordisk.com/news-and-media/news-and-ir-materials.html)
   • 2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market (https://cnbc.com/2026/01/10/2026-is-the-year-of-obesity-pills-from-novo-nordisk-eli-lilly-.html)
   • Novel GLP-1 Promising for Reducing Weight, Glucose (https://medscape.com/viewarticle/new-oral-glp-1-beats-oral-semaglutide-a1c-weight-loss-2026a10006jd)
   • Rybelsus vs Ozempic for weight loss: Which to choose? (https://drugs.com/medical-answers/rybelsus-ozempic-weight-loss-choose-3578038)
   • FDA approves Rybelsus® (semaglutide), the first GLP-1 analog treatment available in a pill for adults with type 2 diabetes (https://prnewswire.com/news-releases/fda-approves-rybelsus-semaglutide-the-first-glp-1-analog-treatment-available-in-a-pill-for-adults-with-type-2-diabetes-300922438.html)
9. Byetta: A Historical GLP-1 Medication in Weight Management
   • Byetta: Dosage, side effects, uses, and more (https://medicalnewstoday.com/articles/drugs-byetta)
   • Does Byetta Help With Weight Loss? Yes, Here’s How - GoodRx (https://goodrx.com/conditions/diabetes-type-2/which-is-better-byetta-victoza-or-bydureon?srsltid=AfmBOopsPmyC4UoBeuczGO98z2oXCC8dKScpSw2aQKFIrWgbA53deIo5)
   • Rx History: The Rise of GLP-1s (https://innovativerxstrategies.com/rx-history-glp1s)
   • Byetta (exenatide) - First-in-Class Incretin Mimetic for Type 2 Diabetes (https://clinicaltrialsarena.com/marketdata/exenatide)
   • Byetta Weight Loss Trial | DiaTribe (https://diatribe.org/diabetes-research/byetta-weight-loss-trial)
10. Zepbound: The Latest GLP-1 Innovation for Weight Management

• Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine | Eli Lilly and Company (https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-showed-superior-weight-loss-over-wegovy)
• Weight Loss: Zepbound More Effective Than Wegovy, Clinical Trial Shows (https://healthline.com/health-news/zepbound-wegovy-weight-loss-clinical-trial-eli-lilly)
• Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst (https://clinicaltrialsarena.com/news/zepbound-will-dominate-obesity-market-following-surmount-5-results-says-analyst)
• Clinical Data, Safety & Study Design | Zepbound® (tirzepatide) (https://zepbound.lilly.com/hcp/clinical-data-weight)
• Zepbound outduels Wegovy in weight-loss clinical trial | Cornell Chronicle (https://news.cornell.edu/stories/2025/05/zepbound-outduels-wegovy-weight-loss-clinical-trial)